Urticaria

Urticarial vasculitis is a rare inflammation of the blood vessels which results in clinical manifestations resembling urticaria with the addition of wheals, there remain no direct treatment options and management involves antihistamines, NSAIDS and ibuprofen to treat the cutaneous manifestations. We were delighted to speak to Dr. Pavel Kolkhir (Charité-Universitätsmedizin Berlin, Berlin, Germany) around the […]

The CRUSE® app has been developed for the self-management of chronic spontaneous urticaria (CSU), and to help physicians develop personalised treatment strategies for patients. touchIMMUNOLOGY were delighted to speak with Prof. Marcus Maurer (Professor of Dermatology and Allergy, Charité – Universitätsmedizin Berlin) about the availability, functions, and clinical implications of the app. Questions: Please could you […]

Phase 2 results of remibrutinib for chronic spontaneous urticaria (CSU) show a fast and sustained response to treatment. While the phase 3b trial is ongoing, touchIMMUNOLOGY were delighted to speak with Prof. Marcus Maurer (Professor of Dermatology and Allergy, Charité – Universitätsmedizin Berlin) about the rationale for studying remibrutinib in relation to CSU and the ongoing […]